Search results
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors
Zacks via Yahoo Finance· 5 days agoPfizer (PFE) closed the latest trading day at $27.66, indicating a -1.32% change from the previous...
Sarepta shares rise as Pfizer DMD trial misses goals By Investing.com
Investing.com· 4 days agoOn Thursday, Piper Sandler maintained an Overweight rating on Sarepta Therapeutics (NASDAQ:SRPT)...
Sarepta Jumps After Rival Gene Therapy From Pfizer Flops
Investor's Business Daily· 4 days agoThe news gives Sarepta Therapeutics (SRPT) an edge heading to June 21, when the Food and Drug Administration will decide whether to fully approve Elevidys for patients with the muscle-wasting ...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 5 days agoPfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin ...
Billionaires Are Buying These 2 Ultra-High-Yield Dividend Stocks Hand Over Fist. Are They Smart Buys...
The Motley Fool· 6 days agoBillionaire investors generally don't necessarily need dividend income to make ends meet. In the...
GSK asks to appeal Delaware ruling allowing Zantac cases to go forward
Reuters via Yahoo News· 7 days agoIf Judge Vivian Medinilla of Delaware Superior Court grants the petition, which is also joined by ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open
Barrons.com· 4 days agoThe drug company Pfizer said a gene therapy it is testing failed to improve motor function in boys...
UPDATE: Pfizer's phase 3 gene therapy trial fails to improve function for boys with Duchenne...
FierceBiotech· 5 days agoPfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor...
Pfizer's Duchenne gene therapy fails in late-stage study
Reuters· 5 days agoThe therapy also did not show a significant difference compared to placebo in secondary goals of the...
Pfizer to have 8 'blockbuster' cancer drugs by 2030
Becker’s Hospital Review· 3 days agoPfizer anticipates developing eight or more potential "blockbuster" cancer drugs by 2030. Pfizer anticipates the new drugs will contribute approximately ...